Compare O'Reilly Automotive Inc. Common Stock (ORLY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
O'Reilly Automotive Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? O'Reilly Automotive Inc. Common Stock trades at $87.78 (market cap $69.59B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: O'Reilly Automotive Inc. Common Stock is far larger — about 18.6× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, O'Reilly Automotive Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| ORLY | TNGX | |
|---|---|---|
Market Cap | $69.59B | $3.75B |
Volume | 3,367,517 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $102.12 | $32.90 |
52-Week Low | $82.73 | $7.50 |
Enterprise Value | $78.92B | $2.77B |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
O'Reilly Automotive (ORLY) trades at $86.03, down 0.72% on the day, amid a mixed technical picture with a bullish overall signal but bearish moving averages. The company reported strong fundamentals with 2025 revenue of $17.78 billion and net income of $2.54 billion, maintaining a robust net income margin of 14.27%. Recent news highlights its defensive positioning in the auto parts market and upcoming Q3 2026 earnings release on October 28, 2026.
The outlook remains positive with a consensus price target of $106.09, implying significant upside. Key opportunities include resilient demand from an aging vehicle fleet and expansion plans in Mexico. Risks involve competitive pressures and potential macroeconomic headwinds affecting consumer spending on auto repairs. Analyst sentiment is strongly bullish with 59.57% buy ratings.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About O'Reilly Automotive Inc. Common Stock
O'Reilly Automotive sells automotive aftermarket parts, tools, supplies, equipment, and accessories. It serves both professional service providers and do-it-yourself customers through its store network.
Read more on ORLY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
